2007
Long-term folow up after non-penetrating glaucoma surgery.
STRNAD, Petr, Jitka SVAČINOVÁ a Eva VLKOVÁZákladní údaje
Originální název
Long-term folow up after non-penetrating glaucoma surgery.
Název česky
Dlouhodobá kompenzace pacientů po nepenetrujících filtračních operacích glaukomu.
Název anglicky
Long-term folow up after non-penetrating glaucoma surgery.
Autoři
STRNAD, Petr, Jitka SVAČINOVÁ a Eva VLKOVÁ
Vydání
Geneva, Switzerland, Book of abstracts 6th I.G.S., Athens, 28.-31.2007, od s. 11-11, 209 s. 2007
Nakladatel
Kenes Int.
Další údaje
Typ výsledku
Stať ve sborníku
Utajení
není předmětem státního či obchodního tajemství
Forma vydání
tištěná verze "print"
Organizační jednotka
Lékařská fakulta
Klíčová slova česky
Hluboká sklerektomie, Glaukom otevřeného úhlu, STAAR implantát, T-Flux implantát, Dlouhodobé výsledky
Klíčová slova anglicky
Deep Sclerectomy, Open Angle Glaucoma, STAAR implant, T-Flux implant, Long-term follow up
Příznaky
Mezinárodní význam
Změněno: 30. 8. 2013 00:54, MUDr. Petr Strnad, Ph.D.
Anotace
V originále
Purpose: To determine the long-term compensation (intraocular pressure, therapy) after non-penetrating filtering glaucoma surgery in patients with open-angle glaucoma. Patients and Methods: A retrospective review contains 86 eyes (56 patients) that underwent deep sclerectomy and had at least 5 years follow-up. The patients were divided into 3 groups according to the type of non-penetrating glaucoma surgery. The first group underwent deep sclerectomy without implant (40 eyes, 26 patients). The second group underwent deep sclerectomy with absorbable collagen implant STAAR (24 eyes, 16 patients). The third group underwent deep sclerectomy with non-absorbable implant T-flux (22 eyes, 14 patients). The average age of the patients in three groups was 63.5, 62.4 and 64.9 years respectively. The average IOP just before surgery was 25.3, 25.9 and 23.7 mmHg and the number of antiglaucoma medications was 3.1, 3.2 and 3.4. The indication for surgery was considered on the basis of insufficient IOP control, usually with the maximal tolerated antiglaucoma medications and the progression of visual field damage. Results: The mean follow-up time in the groups was 81.6 months (range: 64-96 months), 78 months (range: 73-96 months) and 69.8 months (range: 61-85 months). The average IOP at the end of the follow-up time was 17.25, 16.7 and 16.5 mmHg and the number of antiglaucoma medications was 2.1, 1.6 and 0.8. Conclusion: The use of implant in deep sclerectomy enhanced success rate and lowered the need for post-operative medications. Non-absorbable implant had better effect on long-term compensation of the IOP than absorbable one.